Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
NASDAQ:FATE
Price:
1.24
USD
3.33%
Market Closed
Market Cap:
$144.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Fate Therapeutics Inc
NASDAQ:FATE
|
US |
|
Resources & Energy Group Ltd
ASX:REZ
|
AU |
|
B
|
BHP Group Ltd
NYSE:BHP
|
AU |
|
DSV A/S
F:DS81
|
DK |
|
Iren SpA
OTC:IRDEF
|
IT |
|
G
|
Garuda Metalindo Tbk PT
IDX:BOLT
|
ID |
Multiples-Based Value
The Multiples-Based Value of one
FATE
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1.24 USD,
Fate Therapeutics Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
FATE Multiples-Based Value
LOCKED
Multiples Across Competitors
FATE Competitors Multiples
Fate Therapeutics Inc Competitors
Fate Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Fate Therapeutics Inc
NASDAQ:FATE
|
138.4m USD | 21.5 | -1 | 0.4 | 0.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.1B USD | 6.2 | 90.8 | 15 | 20.8 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
362.4B USD | 111.6 | -1 741.9 | 16 180.3 | -1 827 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173B USD | 5.9 | 20.5 | 12.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD | 9.5 | 28.7 | 21.6 | 22.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD | 3.2 | 34.8 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
